In addition, the compensatory upregulation of PKMYT1 has been demonstrated to promote acquired resistance to MK-1775.35,47,48 These evidences indicate the unignorable role of PKMYT1 and suggest that combination of BTZ with PD0166285 may be more optimal than with MK-1775 in anti-cancer therapy. The gene discussed is CASC3; the disease is cancer.